Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.36
COV's Cash to Debt is ranked lower than
76% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.41 vs. COV: 0.36 )
Ranked among companies with meaningful Cash to Debt only.
COV' s 10-Year Cash to Debt Range
Min: 0.1  Med: 0.36 Max: No Debt
Current: 0.36
Equity to Asset 0.50
COV's Equity to Asset is ranked lower than
66% of the 169 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.59 vs. COV: 0.50 )
Ranked among companies with meaningful Equity to Asset only.
COV' s 10-Year Equity to Asset Range
Min: 0.36  Med: 0.48 Max: 0.61
Current: 0.5
0.36
0.61
Interest Coverage 9.76
COV's Interest Coverage is ranked lower than
74% of the 104 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 38.48 vs. COV: 9.76 )
Ranked among companies with meaningful Interest Coverage only.
COV' s 10-Year Interest Coverage Range
Min: 2.33  Med: 10.25 Max: 12.44
Current: 9.76
2.33
12.44
F-Score: 7
Z-Score: 3.89
M-Score: -2.62
WACC vs ROIC
2.13%
15.04%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 19.70
COV's Operating margin (%) is ranked higher than
85% of the 178 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.07 vs. COV: 19.70 )
Ranked among companies with meaningful Operating margin (%) only.
COV' s 10-Year Operating margin (%) Range
Min: 4.31  Med: 20.83 Max: 26.05
Current: 19.7
4.31
26.05
Net-margin (%) 16.58
COV's Net-margin (%) is ranked higher than
88% of the 178 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.54 vs. COV: 16.58 )
Ranked among companies with meaningful Net-margin (%) only.
COV' s 10-Year Net-margin (%) Range
Min: -3.26  Med: 15.35 Max: 19.34
Current: 16.58
-3.26
19.34
ROE (%) 17.99
COV's ROE (%) is ranked higher than
85% of the 174 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.64 vs. COV: 17.99 )
Ranked among companies with meaningful ROE (%) only.
COV' s 10-Year ROE (%) Range
Min: -4.32  Med: 17.96 Max: 20.42
Current: 17.99
-4.32
20.42
ROA (%) 8.73
COV's ROA (%) is ranked higher than
77% of the 183 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.56 vs. COV: 8.73 )
Ranked among companies with meaningful ROA (%) only.
COV' s 10-Year ROA (%) Range
Min: -2.05  Med: 8.03 Max: 9.3
Current: 8.73
-2.05
9.3
ROC (Joel Greenblatt) (%) 54.83
COV's ROC (Joel Greenblatt) (%) is ranked higher than
87% of the 180 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.56 vs. COV: 54.83 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
COV' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 9.46  Med: 49.17 Max: 94.45
Current: 54.83
9.46
94.45
Revenue Growth (3Y)(%) 0.10
COV's Revenue Growth (3Y)(%) is ranked lower than
67% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.00 vs. COV: 0.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
COV' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: 1.55 Max: 9.2
Current: 0.1
0
9.2
EBITDA Growth (3Y)(%) -2.00
COV's EBITDA Growth (3Y)(%) is ranked lower than
66% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.70 vs. COV: -2.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
COV' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: 5.70 Max: 50.9
Current: -2
0
50.9
EPS Growth (3Y)(%) -1.20
COV's EPS Growth (3Y)(%) is ranked lower than
65% of the 125 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.00 vs. COV: -1.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
COV' s 10-Year EPS Growth (3Y)(%) Range
Min: 0  Med: 5.35 Max: 21.9
Current: -1.2
0
21.9
» COV's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

COV Guru Trades in Q2 2014

George Soros 227,000 sh (New)
John Paulson 7,000,000 sh (New)
Eric Mindich 446,000 sh (New)
Louis Moore Bacon 126,022 sh (+1992.69%)
Jeremy Grantham 2,776,488 sh (+31.99%)
Mario Gabelli 637,530 sh (+17.29%)
Ronald Muhlenkamp 182,180 sh (+0.40%)
HOTCHKIS & WILEY 788,700 sh (+0.04%)
First Eagle Investment 1,500 sh (unchged)
Vanguard Health Care Fund 4,994,700 sh (unchged)
Yacktman Fund Sold Out
Joel Greenblatt Sold Out
Manning & Napier Advisors, Inc Sold Out
Robert Olstein Sold Out
Yacktman Focused Fund Sold Out
Ray Dalio Sold Out
Donald Yacktman Sold Out
Private Capital 238,715 sh (-2.09%)
Steven Romick 4,559,929 sh (-6.01%)
John Keeley 40,840 sh (-6.69%)
First Pacific Advisors 4,822,800 sh (-6.98%)
Dodge & Cox 92,017 sh (-9.36%)
Pioneer Investments 1,818,973 sh (-41.91%)
Bill Nygren 160,000 sh (-94.09%)
Paul Tudor Jones 7,416 sh (-97.44%)
» More
Q3 2014

COV Guru Trades in Q3 2014

Steven Cohen 45,000 sh (New)
David Abrams 2,620,000 sh (New)
Paul Singer 502,653 sh (New)
Eric Mindich 3,881,000 sh (+770.18%)
Jeremy Grantham 12,981,012 sh (+367.53%)
John Paulson 12,595,000 sh (+79.93%)
John Keeley 40,840 sh (unchged)
First Eagle Investment 1,500 sh (unchged)
Steven Romick 4,559,929 sh (unchged)
Pioneer Investments 1,770,893 sh (unchged)
Ronald Muhlenkamp 182,180 sh (unchged)
Vanguard Health Care Fund 4,994,700 sh (unchged)
Bill Nygren 160,000 sh (unchged)
George Soros Sold Out
Louis Moore Bacon Sold Out
First Pacific Advisors 4,774,600 sh (-1.00%)
Dodge & Cox 89,017 sh (-3.26%)
HOTCHKIS & WILEY 727,700 sh (-7.73%)
Mario Gabelli 462,251 sh (-27.49%)
Private Capital 157,828 sh (-33.88%)
Paul Tudor Jones 3,900 sh (-47.41%)
» More
Q4 2014

COV Guru Trades in Q4 2014

David Einhorn 851,341 sh (New)
George Soros 197,768 sh (New)
John Burbank 5,094 sh (New)
Eric Mindich 5,481,800 sh (+41.25%)
HOTCHKIS & WILEY 935,100 sh (+28.50%)
Pioneer Investments 2,008,046 sh (+13.39%)
David Abrams 2,950,000 sh (+12.60%)
Steven Cohen 50,000 sh (+11.11%)
Steven Romick 4,651,129 sh (+2.00%)
First Pacific Advisors 4,861,900 sh (+1.83%)
John Keeley 40,860 sh (+0.05%)
Vanguard Health Care Fund 4,994,700 sh (unchged)
First Eagle Investment 1,500 sh (unchged)
Bill Nygren Sold Out
Paul Tudor Jones Sold Out
Paul Singer Sold Out
Ronald Muhlenkamp 181,650 sh (-0.29%)
Private Capital 152,848 sh (-3.16%)
Dodge & Cox 78,686 sh (-11.61%)
John Paulson 10,047,500 sh (-20.23%)
Mario Gabelli 359,176 sh (-22.30%)
Jeremy Grantham 9,819,037 sh (-24.36%)
» More
Q1 2015

COV Guru Trades in Q1 2015

David Abrams Sold Out
Ronald Muhlenkamp Sold Out
Jeremy Grantham Sold Out
Pioneer Investments Sold Out
First Eagle Investment Sold Out
Mario Gabelli Sold Out
Vanguard Health Care Fund Sold Out
Steven Romick Sold Out
First Pacific Advisors Sold Out
Dodge & Cox Sold Out
John Burbank Sold Out
Steven Cohen Sold Out
George Soros Sold Out
David Einhorn Sold Out
Private Capital Sold Out
Eric Mindich Sold Out
HOTCHKIS & WILEY Sold Out
John Keeley Sold Out
John Paulson Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with COV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Covidien PLC

Steven Romick's Top Five Stocks
Steven Romick is the portfolio manager of First Pacific Advisors Crescent Fund. The fund’s investment objective and strategy reports that they “seek to generate equity-like returns over the long-term, take less risk than the market and avoid permanent impairment of capital.” Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 27.50
COV's P/E(ttm) is ranked higher than
55% of the 108 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.60 vs. COV: 27.50 )
Ranked among companies with meaningful P/E(ttm) only.
COV' s 10-Year P/E(ttm) Range
Min: 10.07  Med: 15.16 Max: 27.81
Current: 27.5
10.07
27.81
Forward P/E 22.22
COV's Forward P/E is ranked lower than
54% of the 74 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 21.32 vs. COV: 22.22 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 27.40
COV's PE(NRI) is ranked higher than
52% of the 110 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 28.50 vs. COV: 27.40 )
Ranked among companies with meaningful PE(NRI) only.
COV' s 10-Year PE(NRI) Range
Min: 9.85  Med: 14.91 Max: 27.81
Current: 27.4
9.85
27.81
P/B 4.66
COV's P/B is ranked lower than
68% of the 171 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.86 vs. COV: 4.66 )
Ranked among companies with meaningful P/B only.
COV' s 10-Year P/B Range
Min: 1.64  Med: 2.51 Max: 4.72
Current: 4.66
1.64
4.72
P/S 4.55
COV's P/S is ranked lower than
63% of the 186 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.69 vs. COV: 4.55 )
Ranked among companies with meaningful P/S only.
COV' s 10-Year P/S Range
Min: 1.23  Med: 2.08 Max: 4.61
Current: 4.55
1.23
4.61
PFCF 25.84
COV's PFCF is ranked higher than
58% of the 81 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 28.91 vs. COV: 25.84 )
Ranked among companies with meaningful PFCF only.
COV' s 10-Year PFCF Range
Min: 9.51  Med: 14.39 Max: 362.56
Current: 25.84
9.51
362.56
POCF 21.73
COV's POCF is ranked lower than
57% of the 111 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.68 vs. COV: 21.73 )
Ranked among companies with meaningful POCF only.
COV' s 10-Year POCF Range
Min: 7.39  Med: 11.00 Max: 39.39
Current: 21.73
7.39
39.39
EV-to-EBIT 23.50
COV's EV-to-EBIT is ranked lower than
58% of the 117 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 21.23 vs. COV: 23.50 )
Ranked among companies with meaningful EV-to-EBIT only.
COV' s 10-Year EV-to-EBIT Range
Min: 6.7  Med: 13.30 Max: 76.1
Current: 23.5
6.7
76.1
PEG 13.70
COV's PEG is ranked lower than
95% of the 65 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.87 vs. COV: 13.70 )
Ranked among companies with meaningful PEG only.
COV' s 10-Year PEG Range
Min: 0.41  Med: 2.92 Max: 8.57
Current: 13.7
0.41
8.57
Shiller P/E 30.67
COV's Shiller P/E is ranked higher than
51% of the 79 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.67 vs. COV: 30.67 )
Ranked among companies with meaningful Shiller P/E only.
COV' s 10-Year Shiller P/E Range
Min: 17.76  Med: 21.21 Max: 30.88
Current: 30.67
17.76
30.88
Current Ratio 1.92
COV's Current Ratio is ranked lower than
63% of the 174 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.55 vs. COV: 1.92 )
Ranked among companies with meaningful Current Ratio only.
COV' s 10-Year Current Ratio Range
Min: 0.89  Med: 2.41 Max: 2.85
Current: 1.92
0.89
2.85
Quick Ratio 1.43
COV's Quick Ratio is ranked lower than
57% of the 174 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.68 vs. COV: 1.43 )
Ranked among companies with meaningful Quick Ratio only.
COV' s 10-Year Quick Ratio Range
Min: 0.73  Med: 1.74 Max: 2.17
Current: 1.43
0.73
2.17
Days Inventory 119.42
COV's Days Inventory is ranked higher than
54% of the 173 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 128.70 vs. COV: 119.42 )
Ranked among companies with meaningful Days Inventory only.
COV' s 10-Year Days Inventory Range
Min: 44.38  Med: 104.71 Max: 152.01
Current: 119.42
44.38
152.01
Days Sales Outstanding 49.47
COV's Days Sales Outstanding is ranked higher than
74% of the 154 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 62.15 vs. COV: 49.47 )
Ranked among companies with meaningful Days Sales Outstanding only.
COV' s 10-Year Days Sales Outstanding Range
Min: 52.46  Med: 58.34 Max: 63.06
Current: 49.47
52.46
63.06

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.30
COV's Dividend Yield is ranked lower than
59% of the 146 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.43 vs. COV: 1.30 )
Ranked among companies with meaningful Dividend Yield only.
COV' s 10-Year Dividend Yield Range
Min: 0.39  Med: 1.69 Max: 2.51
Current: 1.3
0.39
2.51
Dividend Payout 0.43
COV's Dividend Payout is ranked lower than
64% of the 83 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.34 vs. COV: 0.43 )
Ranked among companies with meaningful Dividend Payout only.
COV' s 10-Year Dividend Payout Range
Min: 0.19  Med: 0.28 Max: 1.43
Current: 0.43
0.19
1.43
Dividend growth (3y) 39.80
COV's Dividend growth (3y) is ranked higher than
94% of the 54 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.10 vs. COV: 39.80 )
Ranked among companies with meaningful Dividend growth (3y) only.
COV' s 10-Year Dividend growth (3y) Range
Min: 0  Med: -1.05 Max: 66.6
Current: 39.8
0
66.6
Yield on cost (5-Year) 3.80
COV's Yield on cost (5-Year) is ranked higher than
80% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.66 vs. COV: 3.80 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
COV' s 10-Year Yield on cost (5-Year) Range
Min: 1.14  Med: 4.93 Max: 7.33
Current: 3.8
1.14
7.33
Share Buyback Rate 2.80
COV's Share Buyback Rate is ranked higher than
90% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -2.30 vs. COV: 2.80 )
Ranked among companies with meaningful Share Buyback Rate only.
COV' s 10-Year Share Buyback Rate Range
Min: 0  Med: 0.25 Max: -0.5
Current: 2.8

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) (%) 4.30
COV's Earnings Yield (Greenblatt) (%) is ranked higher than
63% of the 179 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.80 vs. COV: 4.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
COV' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 1.3  Med: 7.50 Max: 15
Current: 4.3
1.3
15
Forward Rate of Return (Yacktman) (%) 6.59
COV's Forward Rate of Return (Yacktman) (%) is ranked lower than
63% of the 87 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.10 vs. COV: 6.59 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
COV' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: 6.6  Med: 11.60 Max: 34.1
Current: 6.59
6.6
34.1

Analyst Estimate

Sep15 Sep16 Sep17
Revenue(Mil) 10,979 11,379 11,923
EPS($) 4.31 4.69 4.64
EPS without NRI($) 4.31 4.69 4.64

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, TMO, COO, ISRG » details
Traded in other countries:6COP.Germany,
Covidien PLC formerly known as Covidien Ltd. was incorporated in Bermuda in 2000 as a wholly-owned subsidiary of Tyco International Ltd. In June 2009, Covidien plc announced that one of its subsidiaries has completed the acquisition of VNUS Medical Technologies, Inc. In September 2009, the Company completed the acquisition of Power Medical Interventions Inc. In November 2009, the Company completed the acquisition of Aspect Medical Systems Inc. The Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings. Its products are found in almost every hospital in the United States. Its mission is to create and deliver innovative healthcare solutions, developed in ethical collaboration with medical professionals. It operates through two segments: Medical Devices and Medical Supplies. The Medical Devices segment includes the development, manufacture and sale of endomechanical instruments, energy devices, soft tissue repair products, vascular products, oximetry and monitoring products, airway and ventilation products, and other medical products. The Medical Supplies segment includes the development, manufacture and sale of nursing care products, medical surgical products, SharpSafety products and original equipment manufacturer products. Competitors of Medical Devices segment include diversified healthcare companies, such as Johnson & Johnson, Boston Scientific, Baxter and C.R. Bard. Its Nursing Care products include: Curity and Kerlix and Medical Surgical products include: Medi-Trace. The Company holds more than 13,000 patents and have over 10,500 patent applications pending in the United States and in certain other countries that relate to aspects of the technology used in many of its products. The Company is subject to numerous federal, state and local environmental protection and health and safety laws and regulations both within and outside the United States.
» More Articles for COV

Headlines

Articles On GuruFocus.com
Mairs & Power Balanced Fund Q4 2014 Commentary Mar 31 2015 
Weekly 52-Week Highs Highlight: KR, COV, VRX, NOC Feb 01 2015 
Dravid Abrams and His Top Four Stock Picks Jan 27 2015 
Johnson & Johnson Riding High On Ebola Vaccines Jan 21 2015 
I think Zimmer Will Outperform S&P 500 Performance Dec 04 2014 
Dividend Aristocrats In Focus Part 44: Medtronic Nov 23 2014 
Third Avenue's Top Stocks as of Q3 Nov 16 2014 
Medical Technology Company Offers Investment Opportunity Sep 25 2014 
Gabelli Value 25 Fund Second Quarter Commentary Sep 15 2014 
Paulson, Mindich and Soros Bought Covidien; Should You? Sep 11 2014 

More From Other Websites
Covidien agrees to settle some cases over transvaginal mesh devices Jun 24 2015
Edited Transcript of MDT presentation 10-Jun-15 3:00pm GMT Jun 11 2015
Medtronic (MDT) Earnings Report: Q4 2015 Conference Call Transcript Jun 02 2015
Where Medtronic makes its money after the Covidien acquisition Jun 02 2015
Medtronic Posts Strong Q4 with Earnings, Revenue Beat - Analyst Blog Jun 02 2015
Medtronic Profit Beats Estimates After Covidien Purchase Jun 02 2015
Medtronic (MDT) Likely to Outshine Q4 Earnings Estimates - Analyst Blog Jun 01 2015
Preliminary Transcript of MDT presentation 29-May-15 3:00pm GMT May 28 2015
Edited Transcript of MDT presentation 29-May-15 3:00pm GMT May 28 2015
Acacia Subsidiary Enters Into Settlement Agreement With Covidien LP May 28 2015
Medtronic (MDT) Reveals Impressive Preliminary Q4 Results - Analyst Blog May 20 2015
Medtronic Sales Beat Analysts’ Estimates After Covidien Deal May 19 2015
Medtronic preliminary revenue up on heart devices May 19 2015
Medtronic posts higher preliminary quarterly revenue May 19 2015
John Paulson Continues To Bet On Health Care And TV May 17 2015
The Latest Stock Picks From Cliff Asness, AQR Capital's 13F May 15 2015
Covidien plc (COV), CBS Corporation (CBS): Eton Park’s Picks Handily Beat the Market in Q1 Apr 09 2015
Farallon Capital Increases Position in Covidien Mar 28 2015
Elliott Management exits position in Covidien Mar 04 2015
Chilton Investment Company raises its stake in Covidien plc Feb 24 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK